Safety and immunogenicity of REMUNE super(TM) in HIV-infected Thai subjects

The safety and immunogenicity of REMUNE super(TM), an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ sub(321)), which exhibits a high degree of conservation with the...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1998-02, Vol.16 (2-3), p.142-149
Main Authors: Limsuwan, A, Churdboonchart, V, Moss, R B, Sirawaraporn, W, Sutthent, R, Smutharaks, B, Glidden, D, Trauger, R, Theofan, G, Carlo, D
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The safety and immunogenicity of REMUNE super(TM), an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ sub(321)), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV, the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE super(TM) appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE super(TM) is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE super(TM) to treat HIV-1 infection.
ISSN:0264-410X